Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Pralatrexate for Patients from Prior Allos-sponsored Trials
2011-001309-29Phase 2Terminated
- Sponsor
- Allos Therapeutics
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pralatrexate in breast cancer, sponsored by Allos Therapeutics. Primary endpoint: Long-term safety and efficacy. Started Feb 2012; status: terminated.
02
Drugs
pralatrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-001309-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001309-29.